This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Marino, M.R. Articles by Uderman, H.D. Search for Related Content PubMed Articles by Marino, M.R. Articles by Uderman, H.D. Social Bookmarking                         What's this?

Effect of Nifedipine on the Steady-State Pharmacokinetics and Pharmacodynamics of Irbesartan in Healthy Subjects

Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey

J.L. Hammett

Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey

I. Ferreira

Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey

N.F. Ford

Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey

H.D. Uderman

Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey

Background: In clinical practice, nifedipine has the potential to alter the pharmacokinetics, and therefore possibly the pharmacodynamics and efficacy or safety, of irbesartan. The objectives of the current study were to determine the effects of concomitant administration of nifedipine on the steady-state pharmacokinetics and pharmacodynamics of irbesartan in 12 healthy subjects.

Methods and Results: This was an open-label, randomized, crossover study. Each subject received irbesartan 300 mg once daily for 4 days in one period and irbesartan 300 mg once daily plus long-acting nifedipine (Procardia XL, Pratt Pharmaceuticals, New York, NY) 30 mg once daily for 4 days in the other period. The order of treatment periods was random ized, and a minimum 7-day washout phase separated the two periods. Steady state was achieved by day 3. On day 4, no significant differences were observed between the two treatments with respect to maximum concentration of irbesartan at the end of the dosing interval (C_max) or the area under the plasma concentration versus time curve during a dos ing interval (AUC_tau) of irbesartan. Steady-state C_max and AUC_tau met the criteria for bioequivalence when irbesartan was administered alone or with nifedipine. On day 4, mean plasma renin activity was somewhat higher at every point but one when irbesartan was administered with nifedipine; however, no significant difference was observed between the two treatments in mean 24-hour AUC values. On day 4, there was a modest overall decrease from baseline in mean blood pressure for both treatments. No significant differences were observed between the two treatments in mean 24-hour AUC values for seated diastolic or systolic blood pressure. No serious adverse events were reported.

Conclusions: Concomitant administration of nifedipine 30 mg with irbesartan 300 mg for 4 days in healthy subjects (1) does not alter the steady-state pharmacokinetic parameters of irbesartan, (2) results in Cmax and AUC_tau values for irbesartan that meet the criteria for bioequivalence, and (3) is well tolerated.

Key Words: irbesartan • nifedipine • pharmacokinetics • pharmacodynamics.

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 3, No. 2, 111-117 (1998)
DOI: 10.1177/107424849800300203


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?